We are live on
!
Find out more
Axa Portfolio holdings
AUM
$91.9M
1-Year Est. Return
27.41%
This Fund
S&P 500
This Quarter
Est. Return
+5.33%
1 Year Est. Return
+27.41%
3 Year Est. Return
+100.68%
5 Year Est. Return
+129.89%
10 Year Est. Return
+554.73%
AUM
$32.8B
AUM Growth
+$979M
(+3.1%)
Cap. Flow
-$230M
Cap. Flow
% of AUM
-0.7%
Top 10 Holdings %
Top 10 Hldgs %
18.27%
Holding
1,396
New
147
Increased
409
Reduced
509
Closed
201
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stellantis
STLA
|
+$228M |
| 2 |
Intel
INTC
|
+$84.1M |
| 3 |
Walt Disney
DIS
|
+$74M |
| 4 |
ConocoPhillips
COP
|
+$47M |
| 5 |
EOG Resources
EOG
|
+$44.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lemonade
LMND
|
+$189M |
| 2 |
Berkshire Hathaway Class B
BRK.B
|
+$84M |
| 3 |
AT&T
T
|
+$75M |
| 4 |
State Street SPDR S&P China ETF
GXC
|
+$65.1M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$53M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.35% |
| 2 | Healthcare | 16.7% |
| 3 | Consumer Discretionary | 12.62% |
| 4 | Financials | 10.47% |
| 5 | Industrials | 7.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
SSR Mining
SSRM
$7.1B
| – | – |
-9,400
| Closed | -$189K |
|
1302
Supernus Pharmaceuticals
SUPN
$2.41B
| – | – |
-8,900
| Closed | -$224K |
|
1303
Takeda Pharmaceutical
TAK
$58.3B
| – | – |
-2,375
| Closed | -$43K |
|
1304
Molson Coors Class B
TAP
$7.26B
| – | – |
-384,291
| Closed | -$17.4M |
|
1305
TransDigm Group
TDG
$61.4B
| – | – |
-39
| Closed | -$24K |
|
1306
Atlassian
TEAM
$48.8B
| – | – |
-157,666
| Closed | -$36.9M |
|
1307
Teck Resources
TECK
$32.5B
| – | – |
-72,621
| Closed | -$1.32M |
|
1308
Thor Industries
THO
$3.83B
| – | – |
-29,900
| Closed | -$2.78M |
|
1309
Titan Machinery
TITN
$546M
| – | – |
-31,400
| Closed | -$614K |
|
1310
Toyota
TM
$235B
| – | – |
-795
| Closed | -$123K |
|
1311
TripAdvisor
TRIP
$1.07B
| – | – |
-60,302
| Closed | -$1.74M |
|
1312
TotalEnergies
TTE
$201B
| – | – |
-1,895
| Closed | -$79K |
|
|
UCTT
1313
Ultra Clean Holdings
UCTT
$3.01B
| – | – |
-10,300
| Closed | -$321K |
|
1314
Ubiquiti
UI
$33.5B
| – | – |
-7,600
| Closed | -$2.12M |
|
1315
Unilever
UL
$137B
| – | – |
-1,762
| Closed | -$120K |
|
1316
US Foods
USFD
$20.5B
| – | – |
-82,700
| Closed | -$2.75M |
|
1317
VirnetX Holding Corp
VHC
$48.5M
| – | – |
-6,255
| Closed | -$631K |
|
1318
Vodafone
VOD
$40.6B
| – | – |
-2,028
| Closed | -$33K |
|
1319
Vistra
VST
$47.2B
| – | – |
-44,200
| Closed | -$869K |
|
1320
V2X
VVX
$2.29B
| – | – |
-6,400
| Closed | -$318K |
|
1321
Workiva
WK
$4.13B
| – | – |
-14,700
| Closed | -$1.35M |
|
1322
World Acceptance Corp
WRLD
$894M
| – | – |
-82,365
| Closed | -$8.42M |
|
1323
Xerox
XRX
$435M
| – | – |
-311,500
| Closed | -$7.22M |
|
|
YMAB
1324
DELISTED
Y-mAbs Therapeutics
YMAB
| – | – |
-94,615
| Closed | -$4.68M |
|
1325
Yum! Brands
YUM
$39.9B
| – | – |
-141,747
| Closed | -$15.4M |
|
Similar funds
VI
FA
PBCM
CCAM
GBA
AWP
HI
DCA
Axa's Q1 2021 Portfolio in Review
As of Q1 2021, Axa held 1,396 positions worth $32.8B, up 3.1% from $31.9B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Axa's Q1 2021 filing shows 147 new, 409 increased, 509 reduced and 201 closed positions. Its largest new stake was Wynn Resorts: 347,770 shares worth $43.6M. The largest sale was Lemonade, an estimated $189M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 31% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Axa's largest Q1 2021 buy was Wynn Resorts: 347,770 shares worth $43.6M.
- Axa added most to Stellantis in Q1 2021, an estimated $228M increase.
- Axa's biggest Q1 2021 reduction was Berkshire Hathaway Class B, cutting an estimated $84M.
- Axa fully exited Lemonade in Q1 2021, selling an estimated $189M.
- Axa's ten largest holdings make up 18% of its $32.8B portfolio in Q1 2021.
- Axa opened 147 new positions and closed 201 in Q1 2021.
- Axa's portfolio value rose 3.1% quarter-over-quarter to $32.8B.
Based on Axa's 13F filing for Q1 2021, filed 14 May 2021.